About Axogen
Axogen is a company based in Alachua (United States) founded in 2002. It operates as a HealthTech. Axogen has raised $62.43 million across 11 funding rounds from investors including EW Healthcare Partners, Oberland Capital and PDL BioPharma. The company has 452 employees. Axogen offers products and services including Avance Nerve Graft. Axogen operates in a competitive market with competitors including Humacyte, Avation, CUTISS, BioCircuit and Tissue Regenix, among others.
- Annual Revenue$225.21 M (USD)20.21as on Dec 31, 2025
- Net Profit-$15.7 M (USD)-57.6as on Dec 31, 2025
- EBITDA$659 K (USD)-85.52as on Dec 31, 2025
- Total Equity Funding$62.43M (USD)
in 11 rounds
- Latest Funding Round$31M (USD), Debt – Conventional
Oct 2016
- InvestorsEW Healthcare Partners
& 9 more
- Employee Count452
Products & Services of Axogen
Axogen offers a comprehensive portfolio of products and services, including Avance Nerve Graft.
Nerve graft used for peripheral nerve repair.
Apps and channels of Axogen
its YouTube channel Axogen has 1.16K subscribers and 30 videos.
Videos from Axogen
The most watched videos on Axogen's YouTube channel, Axogen (1.16K subscribers). Click a video to play it here.
More on Axogen.
Funding Insights of Axogen
Axogen has successfully raised a total of $62.43M across 11 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $31 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.43M
- Total Rounds 11
- Last Round Debt – Conventional — $31M
- First Round $12.1M
(Dec 2007)
- Investors Count 10
Latest 10 of 11 funding rounds of Axogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $31M | Debt – Conventional | – | – | – |
| Aug 2015 | $17.1M | Series D | – | – | |
| Nov 2014 | $1.75M | Series D | – | – | |
| Oct 2012 | $20.8M | Series D | – | – | |
| Oct 2011 | $1M | Series C | – | – | – |
| Jun 2011 | $3M | Debt – Conventional | – | – | – |
| Jan 2011 | $3.7M | Series C | – | – | – |
| Jun 2010 | – | Series C | – | – | |
| Jan 2010 | $3.36M | Series C | – | – | – |
| Sep 2009 | $2.62M | Series C | – | – | – |
10 investors in total: 10 institutional.
Investors in Axogen
Axogen has secured backing from 10 investors, including venture fund investors. Prominent investors backing the company include EW Healthcare Partners, Oberland Capital and PDL BioPharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | – | ewhealthcare.com | New York, United States | |
Structured financing solutions are provided for the global healthcare industry by Oberland Capital. | 2013 | oberlandcapital.com | New York, United States | |
Biopharmaceutical company undergoing dissolution and asset distribution processes. | – | pdl.com | - | |
Private investment partnership focused on growth equity investments. | 2010 | jamcapitalpartners.net | St. Simons Island, United States | |
Life science & tech focused VC firm investing in early stage companies in the US | – | cardinalpartners.com | Princeton, United States | |
- | – | denovovc.com | - | |
Early-stage US healthcare investments are made by Accuitive Medical Ventures. | – | amvpartners.com | Duluth, United States | |
- | – | emergentgrowth.com | - | |
Co-founding and investing in tech, med-tech, and biotech companies. | – | synogen.com | - | |
- | – | springboardcapllc.com | - |
Investor details for Axogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Axogen
210 people are tracked at Axogen (55 in leadership, 155 in team); the tracked headcount is 452.
| Name | Role | Group |
|---|---|---|
Jamie Grooms | Director | Leadership |
Scott van Sciever | Regional Sales Director - Breast Specialty U.s. East | Leadership |
Jenna Pascoe | Benefits & Wellness Program Partner | Leadership |
Chad Deville | Regional Sales Director - Breast Specialty U.s. West | Leadership |
Missy Kline | Director Of Quality Assurance | Leadership |
Jessica Terry | Human Resources Business Partner | Leadership |
Peter J. Mariani | EVP & CFO | Leadership |
Erick Devinney | VP of Peripheral Nerve Science & Clinical Innovation | Leadership |
Nathaniel Long | Senior Director, Operations | Leadership |
Angelo G. Scopelianos | Chief Research & Development Officer | Leadership |
Justin Deuerling | Senior Director, Research & Development | Leadership |
Jens Schroeder Kemp | Chief Marketing Officer | Leadership |
Trey Smith | Director, Global Brand Management | Leadership |
Fauzia Makar | Director, Legal Operations And Corporate Counsel | Leadership |
Doris Quackenbush | VP of Sales | Leadership |
Chad McDermott | Regional Sales Director | Leadership |
Michael Dann | Director, National Contracts & Strategic Accounts | Leadership |
Patti Havens | Vice President Human Resources | Leadership |
Siddharth Rao | Global CIO And Vp, It, Cybersecurity, & Commercial Ops | Leadership |
Jonathan Clevenger | Director, Downstream Marketing | Leadership |
190 more people are available in the full profile.
Complete people profiles for Axogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Axogen
Axogen is a publicly listed company on the NASDAQ with ticker symbol AXGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 May 2018
- Listed onNASDAQ: NASDAQ
- Listed entityAxogen, Inc.
- Exchange sectorHealth technology
- ISINUS05463X1063
- Share price$36.13 (-0.14% on the day) · 2026-10-09
- Market capitalisation$2.12B
- EPS (diluted, trailing year)$-0.67
- Volume (last session)929,754
Financials of Axogen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $225.2M | -$15.7M | $659,000 |
| 2024 | $187.3M | -$10.0M | $4.5M |
| 2023 | $159.0M | -$21.7M | -$15.9M |
| 2022 | $138.6M | -$28.9M | -$24.9M |
| 2021 | $127.4M | -$27.0M | -$20.7M |
Detailed financial statements for Axogen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Axogen
4 dated milestones of Axogen across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Axogen is founded.
- Funding First funding round of $12.1M.
- Funding Latest funding round, Debt – Conventional, of $31.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Axogen
Axogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Humacyte, Avation, CUTISS, BioCircuit and Tissue Regenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humacyte.com | 2004 | Morrisville, United States | $424.76M | 70 | Human tissue-based products are developed for vascular disease applications. | |
| avation.com | 1999 | Columbus, United States | $34.92M | – | Wearable tibial nerve stimulation device treats overactive bladder symptoms. | |
| cutiss.swiss | 2017 | Zurich, Switzerland | $94.37M | – | Personalized skin tissue therapy is developed by CUTISS for surgeries. | |
| biocircuit.com | 2016 | Atlanta, United States | $13.65M | – | Non-invasive electrophysiology devices are developed to monitor peripheral nerves. | |
| tissueregenix.com | 2006 | Swillington, United Kingdom | – | 7 | Developer of regenerative medical devices by using cell technology | |
| epineurontech.com | 2016 | Hamilton, Canada | – | – | Medical devices for peripheral nerve injury treatment are provided. | |
| acera-surgical.com | 2013 | St. Louis, United States | $6.32M | – | Synthetic electrospun scaffolds are provided for regenerative medical uses. | |
| tulavi.com | 2020 | Mountain View, United States | $4M | – | Therapeutic devices for neurally mediated diseases are developed. | |
| solsysmedical.com | 1999 | Norfolk, United States | $37.24M | – | Human skin allografts and dressings for wound care are supplied. |
Detailed competitors of Axogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Axogen
The website of Axogen (axogeninc.com) receives about 50K visits a month.
- Monthly visits50K
▼ 30.9% vs previous month
Websites whose visitors overlap most with Axogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
vyvgart.com | vyvgart.com | 100% | – | #381,218 | – |
liverlearning.aasld.org | liverlearning.aasld.org | 97% | – | – | – |
| sightlife.org | 94% | 1.2K | #12,767,729 | View details | |
| plexon.com | 94% | 17.8K | #1,546,194 | View details | |
nerverenew.com | nerverenew.com | 65% | – | #558,800 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Axogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Axogen
Complete news archive for Axogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Axogen
10 companies that operate in the same segment as Axogen (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Axogen
Axogen was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Axogen is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
Axogen is a funded company, having raised a total of $62.43M across 11 funding rounds to date. The company's 1st funding round was a Series C of $2.62M, raised on Dec 2007.
Axogen has 452 employees.
Annual revenue of Axogen is $225.21M as on Dec 31, 2025.
Axogen is dedicated to the development and delivery of technologies and solutions for peripheral nerve repair. The company operates in the healthcare sector, specifically targeting medical professionals and patients with nerve injuries. Solutions provided by Axogen aim to restore feeling and functionality to damaged nerves, improving quality of life. Products like Avance Nerve Graft are utilized to support nerve regeneration and recovery after traumatic injuries.
Axogen offers Avance Nerve Graft.
Yes, Axogen is publicly traded on NASDAQ under the ticker symbol AXGN.
Axogen has 10 investors. Key investors include EW Healthcare Partners, Oberland Capital, PDL BioPharma, JAM Capital Partners, and Cardinal Partners.
Axogen operates through Axogen Corporation.